Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...
Scientists have discovered a way to supercharge the immune system’s T cells by blocking a protein called Ant2, forcing the cells to rewire how they generate energy. This shift makes them more powerful ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 ...
Yuancheng Ryan Lu could barely breathe while he waited for his labmate to adjust the microscope focus. On the slide in front ...
In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
A single-atom nanozyme mimicking cytochrome c oxidase restores mitochondrial energy production in stem cells, shifting their ...
Market · GlobeNewswire Inc. The induced pluripotent stem cell (iPSC) market is experiencing robust growth, with a projected ...
Some jellyfish possess the extraordinary ability to revert their cells back to an earlier developmental stage, effectively ...
European Biotechs are utilizing AI and precision medicines to improve the personalized treatment of cardiovascular disease.
Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical developmentAT-108 is a transformative immunotherapy that triggers ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results